^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Ovarian Cancer
    Drug:NXP900 (Src kinase inhibitor, YES1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Nuvectis Pharma Press Release
    Title:

    FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

    Published date:
    12/01/2022
    Excerpt:
    Nuvectis Pharma, Inc...announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    3326 / 4 - Uncovering the molecular mechanisms which predict sensitivity to a novel src kinase inhibitor NXP900 to inform personalized healthcare strategies

    Published date:
    03/09/2022
    Excerpt:
    Among the most sensitive cell line subtypes are, squamous cell carcinoma, Arid1A mutant ovarian clear cell carcinoma and subtypes of breast luminal A and triple negative breast cancer cell lines. HER2+ breast cancer lines appear insensitive to NXP900 indicating HER2 as a potential driver of resistance to NXP900....Our result provide an indication of patient subgroups which may exhibit optimal therapeutic response to NXP900...